source
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drugSling Therapeutics raised $123 million in a Series C financing round to move its oral drug candidate for thyroid eye disease forward. The capital will fund development of linsitinib, the only late…
- Novartis scraps TREM2 ALS candidate after Phase 2 failureNovartis announced it is halting development of its TREM2-targeting drug VHB937, also known as lifonebart, after the Phase 2 trial in amyotrophic lateral sclerosis (ALS) did not meet its primary en…